Sugi Predict

Sugi Predict / Targets / MAP4K4

MAP4K4

Mitogen-activated protein kinase kinase kinase kinase 4 · O95819 · MAP4K4 on Sugi Atlas →

253,523 patent compounds predicted against MAP4K4, 168,853 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL58274 SCHEMBL58274 1.00 8/20
SCHEMBL69095 SCHEMBL69095 0.67 4/20
SCHEMBL13040 SCHEMBL13040 0.66 4/20
SCHEMBL67376 SCHEMBL67376 0.64 4/20
SCHEMBL77931 SCHEMBL77931 0.62 4/20
SCHEMBL66923 SCHEMBL66923 0.60 4/20
SCHEMBL67192 SCHEMBL67192 0.60 4/20
SCHEMBL68165 SCHEMBL68165 0.59 4/20
SCHEMBL28239 SCHEMBL28239 0.46 4/20
SCHEMBL8975 SCHEMBL8975 0.38 4/20
SCHEMBL68193 SCHEMBL68193 0.67 3/20
SCHEMBL68360 SCHEMBL68360 0.67 3/20
SCHEMBL67345 SCHEMBL67345 0.64 3/20
SCHEMBL67898 SCHEMBL67898 0.64 3/20
SCHEMBL68829 SCHEMBL68829 0.64 3/20
SCHEMBL66986 SCHEMBL66986 0.59 3/20
SCHEMBL67603 SCHEMBL67603 0.59 3/20
SCHEMBL84724 SCHEMBL84724 0.59 3/20
SCHEMBL68662 SCHEMBL68662 0.58 3/20
SCHEMBL67577 SCHEMBL67577 0.58 3/20

Clinical trials — most relevant to MAP4K4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Molecular Mechanisms of Type 2 Diabetes Mellitus PHASE4COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... PHASE2COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PHASE1COMPLETED
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
RASopathy Biorepository nanRECRUITING
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease nanRECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MAP4K4 binder may also engage these)

ProteinNameSimilarity
P97820 — 1.000 P97820 →
TNIK TRAF2 and NCK-interacting protein kinase 1.000 landscape →
P83510 — 1.000 P83510 →
Q9JM52 — 1.000 Q9JM52 →
MINK1 Misshapen-like kinase 1 1.000 landscape →
F1LP90 — 0.999 F1LP90 →
Q23356 — 0.999 Q23356 →
B3M301 — 0.998 B3M301 →
Q95Q98 — 0.998 Q95Q98 →
Q80TZ9 — 0.997 Q80TZ9 →
Q5HZJ0 — 0.997 Q5HZJ0 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.997 landscape →
B4NBP4 — 0.997 B4NBP4 →
Q6C3D7 — 0.997 Q6C3D7 →
Q09228 — 0.997 Q09228 →
SMARCA2 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 0.996 landscape →
Q7RZD3 — 0.996 Q7RZD3 →
O61366 — 0.996 O61366 →
P83038 — 0.996 P83038 →
Q148W8 — 0.996 Q148W8 →
Q60V67 — 0.996 Q60V67 →
A7MBB4 — 0.996 A7MBB4 →
A2QHV0 — 0.996 A2QHV0 →
P48479 — 0.996 P48479 →
BMP2K BMP-2-inducible protein kinase 0.996 landscape →
Q6E3D4 — 0.996 Q6E3D4 →
O01700 — 0.996 O01700 →
F1QIC4 — 0.996 F1QIC4 →
Q19469 — 0.995 Q19469 →
J9VW97 — 0.995 J9VW97 →